Hemolytic anemia and plasma exchange

Basit Öğe Kaydı
dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637
dc.authorscopusidMehmet Hilmi Doğu / 55212747300
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017
dc.contributor.authorSerin, Istemi
dc.contributor.authorDoğu, Mehmet Hilmi
dc.date.accessioned2021-08-31T12:29:29Z
dc.date.available2021-08-31T12:29:29Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractHemolytic anemia is a disease caused by autoantibodies and resulting in various complaints and clinical symptoms. In about half of cases, the cause of autoimmune hemolytic anemia can not be determined. Corticosteroids are the first-line treatment option for warm autoantibody-related hemolytic anemia. In patients who develop steroid side effects or do not respond adequately, other immunosuppressives may be preferred. In case a rapid response is required or fulminant hemolysis occur, human immunoglobulins (IVIGs) may be added to treatment. Finally, plasma exchange (PE) may additionally be utilised. The essence of PE is based on the removal of immune complexes, protein-bound toxins, autoantibodies and high molecular weight solutes and protein-bound solutes. The main clinical aim of the removal of solutes is usually to gain a faster response than immunosuppressive therapy. Studies related to hemolytic anemia and PE are usually based on case reports. Our case report is about a patient with severe IgG subtype hemolytic anemia. The treatment was started with 1 mg/kg methylprednisolone; to which there was no response with weekly rituximab 375 mg/m2 and IVIG administered. Because of unresponsiveness to all of the immunosuppresives, a total of 5 sessions of PE were added to the treatment procedure every other day. After these sessions, the requirement for transfusions has decreased and the patient underwent splenectomy. The patient is currently being followed up only on oral cyclosporine and the last hemoglobin level was 14.7 g /dl. In severe and refractory anemia, especially in the case of cardiovascular imbalance in fulminant hemolysis, PE may be preferred as a third series option after immunosuppressive treatments and play a role as a bridge to splenectomy.en_US
dc.identifier.citationSerin, I., & Dogu, M. H. (2021). Hemolytic anemia and plasma exchange. Transfusion and Apheresis Science, 103245.en_US
dc.identifier.doi10.1016/j.transci.2021.103245en_US
dc.identifier.issn1473-0502en_US
dc.identifier.pmid34412947en_US
dc.identifier.scopus2-s2.0-85112740635en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103245
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2012
dc.identifier.wosWOS:000697004600014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorDoğu, Mehmet Hilmi
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutoantibodiesen_US
dc.subjectHemolytic Anemiaen_US
dc.subjectImmunosuppressiveen_US
dc.subjectPEen_US
dc.titleHemolytic anemia and plasma exchangeen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
137.pdf
Boyut:
294.37 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu